Built in Germany for a Global Mission

From Germany, a disciplined material platform for diabetic wound care

DiasilX is developing a shape-defined natural mineral wound-interface platform for the global care pathway before irreversible limb loss.

Investor Access
537M
People Living With Diabetes
19–34%
Lifetime DFU Risk Among People With Diabetes
Repeat
Long-Term Care Market

A painful clinical gap.
A recurring care market.

Difficult diabetic wounds are not a one-visit problem. They pull patients, clinicians, dressings, monitoring, outpatient care, and hospital resources into a long and expensive loop.

O1

High-Cost Burden

DFU sits at the intersection of chronic disease, wound care, infection risk, hospitalization, and limb-loss prevention — a place where better tools matter economically.

O2

Repeated Use Case

Hard-to-heal wounds require repeated dressing changes, follow-up, and clinical decision points, creating a recurring product and care pathway rather than a one-time purchase.

O3

Category Potential

DiasilX is not positioning itself as another dressing SKU. The ambition is a mineral-defined wound-interface category with IP, validation, and partner-ready development milestones.

Modern science, ancient materials, and a mission beyond the wound.

We are not just looking for another new ingredient. We are rethinking what a material itself can do.

In an age that often reaches for more complex molecules and more expensive technologies, DiasilX returns to an older and quieter starting point: materials left by nature.

We use modern science to understand ancient materials again, define them with discipline, and bring them back to today's medical-device pathway under today's standards.

Nature gave it shape.Time gave it silence.Germany gives it discipline.DiasilX gives it a new mission.

EU MDR Class IIa

European medical-device discipline and staged evidence planning from the beginning.

Material Discipline

Natural materials are treated as controlled, defined, and evidence-led development candidates.

🔬

NVIDIA Inception

Internal analysis workflows and third-party testing partnerships support staged development decisions.

Difficult wounds are not flat surfaces. They are uneven, deep, and biologically shielded.

Biofilm barriers, irregular wound geometry, variable depth, and uneven exudate make contact with a wound surface difficult. DiasilX starts from that reality: before adding another active ingredient, we ask how a material interface should meet a wound that is never simple.

Minerals engineered by shape.
Wound care built for the hard cases.

Difficult wounds are not just open skin. They are hostile, dynamic surfaces. DiasilX is developing mineral architectures designed to work with that reality.

M1

Hostile-Surface Design

Built for high-burden diabetic wound environments, with detailed implementation kept confidential until priority filings are secured.

M2

Stage-Aware Materials

A family of mineral architectures designed around changing wound conditions, not a one-size-fits-all powder.

M3

Category Creation

A simple thesis with large consequences: the shape of a mineral can become a wound-care design variable.

Science for the curious.
IP discipline for the serious.

DiasilX is built to be understood in public without giving away the parts that matter. The website gives investors the thesis; confidential review gives qualified partners the details.

S1

Science

A public explanation of why material architecture may become a missing dimension in wound care.

S2

IP Moat

A confidential protection strategy across material architecture, process controls, and wound-care application.

S3

Qualified Review

Investors, CROs, and strategic partners can request a scientific brief or CDA/NDA discussion.

Let's advance wound care together

Interested in our technology, research collaboration, or investment opportunity? We'd love to hear from you.